Personalised medicines: the new frontier, the rise of CRISPR-based therapies in oncology
The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene autotemcel, branded Casgevy, for severe sickle cell disease, and later the EMA approved it for use in the EU. NICE has since recommended Casgevy […]